Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer

作者：Woff Erwin^*; Hendlisz Alain; Garcia Camilo; Deleporte Amelie; Delaunoit Thierry; Marechal Raphae; Holbrechts Stephane; Van den Eynde Marc; Demolin Gauthier; Vierasu Irina; Lhommel Renaud; Gauthier Namur; Guiot Thomas; Ameye Lieveke; Flamen Patrick

来源：European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43(10): 1792-1801.

DOI：10.1007/s00259-016-3365-x

• Early metabolic response assessment
• FDG PET-CT
• Tumoral heterogeneity
• Metastatic colorectal cancer
• Targeted therapy

The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient's unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine.
This substudy was performed within the framework of a wider prospective multicenter study on the predictive value of early FDG PET-CT response assessment (SoMore study). A lesion-based response analysis was performed, including all measurable lesions identified on the baseline PET. On a per-patient basis, a descriptive 4-class response categorization was applied based upon the presence and proportion of non-responding lesions. For dichotomic response comparison, all patients with at least one resistant lesion were classified as non-responding.
On baseline FDG PET-CT, 124 measurable "target" lesions were identified in 38 patients. Early mR assessments showed 18 patients (47 %) without treatment resistant lesions and 12 patients (32 %) with interlesional response heterogeneity. The NPV and PPV of early mR were 85 % (35/41) and 84 % (70/83), respectively, on a per-lesion basis and 95 % (19/20) and 72 % (13/18), respectively, on a dichotomized per-patient basis.
Early mR assessment performed after one cycle of sorafenib-capecitabine in mCRC is highly predictive of non-response at a standard response assessment time. The high NPV (95 %) of early mR could be useful as the basis for early treatment discontinuation or adaptation to spare patients from exposure to non-effective drugs.

• 出版日期2016-9